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Abstract  
Objective: This work evaluates the potential of using fresh milk to deliver theophylline to children. 25 
Methods: Theophylline-fresh milk systems were prepared using different solids ratios (0:1 to 1:0) and three 
fat contents in commercial milks (low, medium and high), which were spray-dried at different inlet air 
temperatures (Tinlet – 105, 130 and 150°C). The process was evaluated for yield and the resulting powders 
for moisture content, particle size and shape, density and wettability. Theophylline-milk potential 
interactions (DSC and FT-IR), and chemical (theophylline content) and microbiological stability of powders 30 
(shelf and in-use) were also evaluated.  
Key findings: The production yield (13.6-76.0%), moisture content (0.0-10.3%) and contact angles in water 
(77.29–93.51◦) were significantly (p<0.05) affected by Tinlet, but no differences were found concerning the 
mean particle size (3.0-4.3µm) of the different powders. The milk fat content significantly (p<0.05) 
impacted on the density (1.244–1.552g/cm3). Theophylline content remained stable after 6 months of 35 
storage, prior to extemporaneous reconstitution. After reconstitution in water, low fat milk samples (stored 
at 4°C) met the microbial pharmacopoeia criteria for up to 7 days. No theophylline-milk components' 
interaction was observed. 
Conclusion: Spray-dried milk-composed powders may be used as vehicles for theophylline delivery in 
paediatrics following further characterization and in vivo evaluation. 40 
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1. Introduction 
A paediatric patient belongs to a distinct and heterogeneous group regarding pharmacotherapeutic 70 
requirements (1,2). It is well established that children are not small adults and, therefore, drug 
formulations for paediatrics should be adapted to suit children’s age, size and physiology, as well as 
treatment needs. Medicines' design is therefore critical to achieve not only safe and accurate dosing of 
drugs, but also to enhance compliance and improve clinical outcomes in children. To tackle this problem 
new paediatric regulations and development programs have recently been issued by the European 75 
Medicines Agency (EMA) (3) and the World Health Organization (WHO) (4,5). 
Children are, however, especially challenging (6) since they are continually growing up, thus 
presenting constantly evolving pharmacokinetic parameters, and many existing medicines were not 
designed or tested ab initio having these considerations in mind. Moreover, many drugs are unavailable as 
paediatric formulations, requiring the use of unlicensed (off-label) medicines, by manipulation of existing 80 
dosage forms designed for adults. Often, these are compounded with excipients which are toxic to children 
and are administered without considering that paediatric patients do not have fully developed enzymatic 
and immunologic systems (2,7,8). 
The oral route of administration remains the preferred one and liquid dosage forms (e.g. solutions 
and suspensions) are widely used in paediatrics' daily clinical practice. These dosage forms are preferred 85 
among children (< 5 years old) due to their ease on swallowing and dose adjustment, but can compromise 
the patient’s compliance (e.g. bitter taste), suffer from dose inaccuracy and lack long term chemical, 
physical and microbiological stabilities. Small-sized multiunit solid dosage forms, such as minitablets (9,10), 
pellets (11) and granules (12), which do not present the disadvantages discussed for liquids, become a 
better option in grammar school children’s age (> 6 years old) due to the ease of administration (2,13). 90 
However, as discussed before, the paediatric group encompasses so many different individual 
characteristics and is so diverse that it is almost impossible to develop a single formulation which is 
accepted across the group (2).  
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Compliance with drug therapy in paediatrics is related to the acceptability of the formulations by 
patients. In some situations (e.g. bitterness of the API) nurses, parents and even caregivers are encouraged 95 
to mix the medicines with food (e.g. juices and infant milk formulas) disregarding drug stability  issues (14). 
In this study, milk was chosen as a matrix for potential drug delivery in paediatrics because it is a 
worldwide accepted food (in fact, the primary nutritional source in the newborns) which presents good 
organoleptic and physicochemical properties for the intended use. As a complex system − milk is 
simultaneously a solution (dissolved proteins, minerals and vitamins), a suspension (whey proteins) and an 100 
emulsion (lipids and lipophilic vitamins) − it incorporate drugs with different solubilities and thus represent 
a good matrix for paediatric drug delivery. In fact, milk components (e.g. caseins) have already been used as 
vehicles for bioactives (15) but a few studies have explored its potential in paediatric drug delivery (16). 
Milk-based oral formulations recently described in the literature consisted of alkaline/ethanolic solutions, 
containing different drugs, which were mixed with fresh milk immediately before administration to patients 105 
(17) or used skimmed milk to formulate solid dispersions of poorly water solubility APIs (18,19). In these 
cases, extra excipients will be needed in the formulation, increasing the risk of toxicity or, simply increasing 
the complexity of the final product. 
Milk is commercially available as powdered or fresh milk. The latter can be easily converted into 
powdered milk by spray-drying, which is the most common method for dehydrating milk. The process 110 
promotes the stability of the final product and, at the same time,  lowers the production costs due to the 
very short time of heat contact and high rate of evaporation (20,21). Consequently, it is possible to 
hypothesize that a drug-milk system can be converted into a powdered formula by spray-drying. The final 
product is expected to be both more stable in the long term (particularly by comparison with liquid dosage 
forms) and amenable to be used in a broader age group of patients (as compared to other solid dosage 115 
forms). The use of fresh, as compared to powdered milk, to incorporate the drug presents the advantage of 
promoting uniformity of contents and solubilisation of poorly water soluble drugs. Theophylline (1,3-
dimethyl-7H-purine-2,6-dione) was considered in the study as a model drug, based on therapeutic 
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relevance in the treatment of acute and chronic asthma in children (22), and the possibility of extrapolating 
these results to other drugs that are known for their narrow therapeutic index.  120 
The novelty of the work resides on the use of spray-dried fresh milk as a platform to deliver drugs in 
paediatrics, addressing three main concerns of Health Authorities (23) regarding paediatric medicines: a) 
safety of excipients, b) appropriateness of formulation and dosage form according to the age group 
considered, and c) dosing flexibility, accuracy and practical handling. 
 125 
 
 
 
2. Materials and Methods  
2.1. Materials 130 
Fresh commercial milks (Mimosa, Lactogal Produtos Alimentares S.A., Portugal) with different fat 
contents (per 250ml), Low Fat Milk (LFM − 0.3g), Middle Fat Milk (MFM − 4.0g) and High Fat Milk (HFM − 
9.0g), were used in the study. Anhydrous theophylline, diiodomethane, p-aminobenzoic acid (PABA) and 
acetonitrile (HPLC grade) were all from Sigma Life Science (Germany); ammonium acetate (Merck, 
Germany) and methanol (Fischer Chemical, USA). Deionized water (W, 18.2MΩ.cm, Milli-Q system, Merck 135 
Millipore, USA) was used throughout the study. All other reagents were of analytical grade. 
 
2.2. Methods 
2.2.1. Preparation of theophylline : milk systems 
  A theophylline stock solution (7.5mg/ml deionized water, 900rpm, 30min) was used to incorporate 140 
known amounts of drug into constant volumes of each type of milk to obtain theophylline:milk solids ratios 
of 0.08:1, 0.16:1, 0.31:1, 0.62:1 and 1:1 (w/w, Table 1 and Annex 1). Controls of fresh milks and aqueous 
theophylline solutions (0:1 and 1:0) were considered. Altogether theophylline was present in quantities 
from 0 to 2.5g per 2.5g of powdered milk. 
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2.2.2. Spray-drying 145 
Spray-drying of theophylline in milk systems was performed in a Mini Spray-Dryer B-191 (Büchi 
Labortechnik GmbH, Switzerland). The feed solutions were atomized (1mm diameter static nozzle) using a 
feed liquid rate of 4 ml/min (i.e. 20%), an atomizing airflow rate of 600L/h and a constant aspiration rate of 
100%; settings were kept constant throughout the study. Three different inlet/outlet air temperatures were 
used: 105/68C; 130/87C; and 150/100C. The outlet air temperature was recorded after the beginning of 150 
the drying process, and although it depends on the instrument settings, variations were smaller than ±1⁰C. 
Theophylline controls were atomized at a single inlet/outlet air temperature (130/87C). The solutions 
were fed into the spray-dryer chamber, once the desired inlet temperature was achieved. The spray-dried 
samples were collected and stored at room temperature (24±1C) and controlled humidity (RH=65%). 
 155 
2.2.3. Characterization of spray-dried powders and process 
Yield and moisture content of powders: the yield of the process was obtained from the ratio between the 
mass of powder collected from the outlet chamber and the sum of milk solid components and theophylline 
masses; moisture content of dried powders was determined by the water loss on drying of powders dried 
in an oven (Memmert, Germany) at 75±3C, until constant weight. Particle size and shape analysis: The 160 
mean particle’s diameter by number was determined by optical microscopy (BX51, Olympus, Japan), after 
suspension of powder specimens in liquid paraffin. To guarantee a normal distribution of data more than 
200 particles were measured from photographs (5 different fields; 50x magnification, Olympus Stream 
Essentials Software, Olympus, Japan) and classified as spherical or non-spherical (ICH Topic Q4B (24)) upon 
observation of random fields by scanning electronic microscopy (SEM after coating with chromium; JEOL 165 
JSM-T330A, JEOL, Japan). Density: Helium pycnometry (AccuPyc 1330, Micromeritics, USA) was used to 
measure the density of spray-dried milk powders (n=3). Contact angle and surface free energy 
determinations: Contact angles were measured by tensiometry (Wilhelmy plate method, K100, Krüss 
GmbH, Germany) once spray-dried powders were made to adhere to a rectangular support (20x20mm). 
The testing liquids (water and diiodomethane) were placed in a glass jar (ca 50cm3) which was raised at 6 170 
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mm/min until the plate was submersed for 2mm at 25±0.5°C (n=3, Thermo Haake GmbH, Germany). 
Contact angles and surface free energies were calculated from the Wilhelmy equation and the works of 
adhesion and cohesion, and spread coefficients were calculated for both the raw materials (different fat 
content milks and theophylline) and dried samples according to Wu equations (LabDesk v. 3.2, Krüss GmbH, 
Germany), as described in the literature (25). 175 
 
2.2.4. Evaluation of potential interaction between theophylline and milk components 
Fourier Transform Infrared Spectroscopy (FT-IR): Infrared spectra were collected for raw materials and 
processed powders (Affinity-1 FT-IR, Shimadzu Corp., Japan) in potassium bromide disks (1mg sample in 
100mg potassium bromide) prepared by gently grinding the materials in a mortar prior to compaction 180 
(40kN). Data was recorded in the range 4000–400cm−1, with resolution of 4cm-1, providing an average 
spectrum from 30 scans (OriginPro software, OriginLab, China). Differential Scanning Calorimetry (DSC): 
Calorimetric studies were performed in a differential scanning calorimeter (DSC, Q200, TA Instruments, 
USA) in the range of 0 to 285°C, at a heating rate of 10°C/min. Powdered samples were submitted to two 
heating cycles in sealed pin holed pans. Data was analyzed with the Universal Analysis 2000 v.4.7A software 185 
(TA Instruments, USA). 
 
2.2.5. Quantification of theophylline in the spray-dried powders 
Theophylline was quantified by high pressure liquid chromatography (HPLC, Merck®-Hitachi 
Lachrome, Germany) at room temperature and detection at =272nm. A Merck® analytical Purospher C18 190 
column (250 x 4mm internal diameter; particle size 5µm) and a Purospher C18 guard column (4 x 4mm 
internal diameter; particle size 5µm) were used PABA (5μg/mL) was included in every sample as an internal 
standard (IS). The eluent (10mM ammonium acetate buffer: acetonitrile: methanol in 90:5:5 v/v/v) was run 
under isocratic conditions at 1mL/min flow rate. Appropriately diluted samples were centrifuged 
(2000rpm/10 min) prior to injection (20µl) and analysed in triplicate. Standard solutions of theophylline (0.2 195 
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to 75μg/ml) and PABA working solution (100µg/ml), were prepared in water. The method was previously 
validated for specificity, linearity, accuracy, precision and recovery, according to ICH guidelines (26).  
 
2.2.6. Stability studies  
Shelf stability of powders and in-use stability, after reconstitution in water, was performed in a 200 
random set of seven spray-dried samples (out of 54 possible samples, according to a complete factorial 
design of experiments). Powders were manufactured in the same week the study started (time 0) and were 
retested (theophylline content and microbial burden) after 6 months of storage (25°C / 65% of RH).  
Powders (2g) were reconstituted in water (15mL), in a 20 mL amber flask and shaken for 1min and 
equally divided into two other containers (stored at 4°C and 25°C respectively). At specific time points (0, 1, 205 
2, 7, 14 and 28 day) 1mL aliquot of each extemporaneous preparation, was taken for drug quantitation and 
microbiological assay.  
Total aerobic viable microorganisms, total number of yeasts and moulds, and absence of 
Escherichia coli (both in powders and reconstituted samples) was assessed according to the European 
Pharmacopeia (27). 210 
 
2.2.7. Statistical Analysis 
Analysis of data was performed using SPSS v.22.0 (IBM®, USA) for descriptive analysis of categorical 
and scalar variables. The results were further analyzed using one-way ANOVA followed by post-hoc 
Bonferroni test (p < 0.05). Unless otherwise stated, data is represented as mean with coefficients of 215 
variation smaller than 2% for all experiments. 
 
 
 
 220 
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3. Results  
 
3.1. Properties of the spray-dried powders and characterization of the production process 
 Results obtained for the different medicinal powders produced by varying the milk fat content and the 225 
amount of theophylline, as well as for samples containing only milk (LFM, MFM and HFM), or theophylline, 
used as controls are given in Table 1 and Annex 1 and statistical analysis in Table 2. 
3.1.1. Yield and moisture content (MC): Aqueous solutions of theophylline containing the same fractions 
as those present in the studies with different milks (controls) have shown yields within the range of 19.18-
30.04% and residual water content within the range of 0.4 – 2.0% (Annex 2). These experiments have 230 
shown acceptable moisture contents but low yields of collected theophylline, anticipating the need of 
optimization for industrial scaling up. The spray-dried milk powders, regardless of the variables considered, 
presented a yield in the range of 25.2-73.3 (Table 1). Powders atomized at 130°C presented the highest 
yields, which were significantly different (p<0.05, Table 2) from those powders produced at other 
temperatures, suggesting that Tinlet is a key factor in the manufacture of the product. In contrast, neither 235 
the theophylline fraction in the powder, nor the fat content of the fresh milk, affected the yield of the 
powders (p>0.05, Table 2). The MC of the spray-dried milk powders ranged between 0.0 – 10.3% and, as 
the Tinlet increased, the moisture content of powders decreased significantly (p<0.05). The absence of 
significance of either fat content or theophylline fraction on the yield or moisture content was anticipated 
due to the inexistent relationships between these variables (Table 1). 240 
3.2.1. Particle size and shape: Microscopic evaluation of powdered samples revealed that, overall, particles 
acquired a spherical shape on drying (Figure 1, a-b). However, some samples have shown suspended needle 
shaped and crystalline particles, assumed to be of theophylline (as observed under polarized light 
microscopy; Figure 1, c-d), as this was particularly relevant in the samples with higher theophylline : milk 
ratios (0.31:1, 0.62:1, and 1:1). The particles’ size were in the range of 3.0 - 4.3 µm and the span values 245 
indicated narrow size distributions (Table 1). The variability observed for the data collected from this set of 
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experiments was reflected on the absence of significant effect on the size of particles by each of the three 
factors considered (Tinl, fat content and theophylline fraction) (Table 2). 
3.2.2. Density: The density of powders was in the range 1.426–1.552g/cm3 for LFM, 1.386–1.455g/cm3 for 
MFM and 1.244–1.437g/cm3 for HFM (Table 1). This property was significantly affected by the fat content 250 
of milk (p < 0.05) but neither the theophylline fraction, nor Tinlet, significantly influenced the density of the 
powders (Table 2). However, although not significant, a slight increase on the density was observed with 
the increase in theophylline fraction, in line with the density of control samples (milk only, data not shown). 
3.2.3. Surface properties of powders: The contact angle of theophylline in water (77.33°) was smaller than 
that of pure milk powders (79.76-93.51°). In average, LFM produced medicinal powders with lower contact 255 
angles in water (80.62-87.17°) than MFM (79.76-93.45°) and HFM (77.29-93.51°). Table 1 summarizes the 
results from contact angles, γs and γ
p, respectively total and polar component of surface energy, of each 
spray-dried powder. The two interrelated properties were significantly affected by Tinlet , and marginally by 
the fat content of milk. Only the polar component (γp) was also significantly affected by the milk fat content 
(p < 0.05), with the MFM samples being significantly different from the other two (Table 2). LFM powder 260 
presented the highest surface free energy range (42.35-52.44mJ/m2) and polar component range (5.08-
12.30mJ/m2). The HFM powders atomized at 105°C presented higher γs and γ
p (41.33-49.76 mJ/m2 and 
7.27-10.18 mJ/m2, respectively) than the ones atomized at the other inlet air temperatures (130 and 
150°C). After resting at room temperature (25°C, overnight), these values decreased slightly (data not 
shown) reflecting some stabilization of the powders' surfaces immediately after processing. To anticipate 265 
the interaction between theophylline and the matrix formed by milk components in the drug-loaded dried 
particles, the works of cohesion (Wc) and adhesion (Wa) were calculated for the controls (theophylline and 
milk) (Table 3). Wc of theophylline (98.48mJ/m
2) was higher than the ones observed for the three milks 
(78.26-97.26mJ/m2), particularly for LFM before drying. Once controlled solutions were dried, the particles 
obtained presented a similar pattern with the exception of LFM dried at 105°C (104.88mJ/m2). This sample 270 
might have been affected by the higher moisture content in comparison to the other samples (data not 
shown). The Wc was consistently lower in comparison to the Wa (85.96-97.83mJ/m
2) in all samples, except 
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in the sample mentioned earlier (101.50mJ/m2) anticipating a fair incorporation of theophylline molecules 
into the milk components. Calculated spreading coefficients in general have shown positive values of 12 
(one sample had a negative value, Table 3) increasing with the content of fat in the milk. These values were 275 
in line with those obtained for the dried powders and confirm the spreading of milk components on 
theophylline molecules. 
 
3.3. Evaluation of drug-milk potential interaction 
3.3.1. Fourier Transform Infrared Spectroscopy (FT-IR): The FT-IR spectra from all samples and controls were 280 
evaluated but, since the different Tinlet considered did not produce products with different spectra, only the 
spectra of the spray-dried milk powders atomized at 105°C are presented as an example (Figure 2). 
Theophylline (raw material) showed bands at 3120.96cm-1 (N-H stretching), at 1716.72cm-1 and 1668.50cm-
1 (C=O stretching, amide I), at 1566.27cm-1 (N-H bending, amide II) and the N-H wagging at 742.63cm-1 (28). 
For the samples with milk, regardless the fat content, it was possible to identify bands at 3468.16 – 285 
3304.20cm-1 (O-H and N-H stretching in the protein structure), at 1660.78 – 1643.42cm-1 and 1546.98 – 
1545.05cm-1 (amides I and II, respectively, in the proteins’ structure) and in the region of 1200 – 900cm-1, 
corresponding to the so called “saccharide” bands. For the middle and high fat milk powders it was also 
possible to identify a region at 2924.21 – 2854.77cm-1 originated by the vibrational C – H stretching of the 
fatty acids and a single high intensity band at 1745.69cm-1 caused by C=O group due to the stretching of the 290 
fatty esters molecules (29). When the fraction of theophylline increased in the dried powders, the signals 
due to the molecule of theophylline started to be more intense than the signals due to the milk 
components, as expected. For the 0.08:1 and 0.16:1 solids ratio samples, the N – H stretching at 
3120.96cm-1 was not observed. The potential formation of an imine group due to the interaction between 
theophylline and milk components in the dried powders, reflected by new bonds formation, would have 295 
been observed in the 1647 – 1630cm-1 region; but it was neither observed in samples considered 
immediately after spray-drying or after storage (6 months) of dried powders. 
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3.3.2. Differential Scanning Calorimetry (DSC): The thermograms obtained from calorimetric studies of the 
spray-dried milk samples manufactured at 150°C are shown in Figure 3. For this process temperature, 
theophylline presented a sharp endotherm event at 272.75°C (positive control), whereas spray-dried milk 300 
powders presented a broad band that corresponds to the dehydration of the samples (40 - 110°C) and two 
other small bands corresponding to milk components, such as lactose or proteins (162.59-167.04°C and 
198.52-199.12°C) (30). For the powders produced from middle and high fat milks, endothermic (on heating 
the sample) and exothermic (on cooling) events were also observed between 30-40°C (melting followed by 
recrystallization of fat content). Above 0.31:1 solids’ ratio samples, a broad band started to appear 305 
between 233.30-249.11°C. As the theophylline fraction increased in the formulation, a shift of this peak to 
higher temperatures between 257.68 and 266.88°C was observed. The endothermic events characteristic of 
the milk components (negative controls) were also observed in the spray-dried milk powders, although the 
enthalpies of fusion were higher for the latter. The glass transition temperature (Tg = 30.72°C) was distinctly 
observed in the LFM samples in contrast to the MFM and HFM samples. It is worth noting that no other 310 
differences in the thermograms were observed for the different temperatures. Although thermograms 
were complex due to the complexity of the samples, the patterns of the curves were reproducible 
particularly when the second heating stage was applied to samples. 
 
3.4. Quantification of theophylline in powders 315 
The theophylline assay in freshly prepared theophylline-milk solutions has shown a slight increase 
on drug content as the drug fraction increased in formulations, independently of the other factors (Tinlet and 
fat content of milks, data not shown). The quantification of theophylline in the spray-dried powders has 
shown that Tinlet and milk fat content were not significant and did not affect the recovery and quantification 
of theophylline from samples (Table 1). A dramatic decrease on drug content above 0.31:1 was obtained 320 
and became particularly significant (p < 0.05) for the 0.62:1 and 1:1 ratios, and higher processing 
temperature and milk fat content (Table 2) suggesting that drug recovery from samples was not complete. 
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Overall, theophylline content was within 2-7% variation in the different powder samples assayed (data not 
shown). 
 325 
3.5. Stability 
The stability in-use was assessed after the reconstitution of dried powders in water immediately 
after production. After storage at room temperature (25°C) microbial criteria were met at day 1 by all 
samples, regardless of fat content and processing conditions. At 4°C, microbial criteria were met by all 
samples up to 2 days, but only LFM samples met the criteria 7 days after reconstitution. Yeasts and E. coli 330 
were absent in every sample tested. Theophylline content in solution remained stable over the 28 days of 
test, regardless of fat content and microbial growth (not shown). It is also worth to mention that samples 
dried at lower inlet air temperatures presented lower microbial growth. 
Regarding the medium to long term stability of spray-dried powders, microbial criteria were met 
only by LFM samples and theophylline quantification has shown that there was no decrease in content 335 
after 6 months of storage. 
 
 
4. Discussion 
It was expected that as the inlet air temperature increased, the yield also increased, but that was 340 
not verified, in contrast to some previous studies (31) in which only the effect of Tinlet was considered. 
However, the complex matrix (e.g. protein, fat and lactose) used in the present work can justify the results 
obtained. For instance, it is known that powdered hygroscopic lactose is sticky in the presence of residual 
water (20) and that the yield at high Tinlet (32) was diminished. Furthermore, molten milk fat concentrated 
at the surface of the particles (33,34) at high temperatures (e.g. 150⁰C), increases stickiness of the product 345 
to the drier’s wall, with a decrease in yield. The yield of spray-dried theophylline (control) was significantly 
smaller than those of drug-loaded milk powders, suggesting that during the process theophylline molecules 
have bound to the milk components (e.g. proteins (15)), thus reducing drug loss on drying. 
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The powder moisture content may have a significant impact on the long-term stability, both in 
terms of drug degradation and microbial growth (35). As Tinlet increased the residual water in the spray-350 
dried powders decreased, as corroborated by other studies (36,37). After spray-drying lactose becomes 
largely amorphous and highly hygroscopic (20), as observed in LFM samples, showing a Tg (ca 30.72°C) 
considerably lower than the Tg of amorphous lactose (97–116°C) (20,38), emphasizing the care required to 
assure optimal storage conditions (RH and temperature) of the powders. This Tg was neither found in MFM, 
nor in HFM powders, which might have embedded the lactose or, simply overlap the thermic event due to 355 
the proximity of the melting range of fat components (38).  
 Sizing and shaping of particles by microscopy confirmed the expected spherical shape and narrow 
size distribution of dried particles (3.0 to 4.3 µm in diameter) which are appropriate for reconstitution in 
water (39). These properties were independent of the factors considered (Tinlet, theophylline fraction), in 
contradiction to other studies (31,37) which have concluded that particle size was influenced by different 360 
Tinlet because higher temperatures of atomization led to an expansion of the final particles, whereas lower 
temperatures promoted shrinkage of their structure. In the present case the fat component may have 
accommodated the impact of Tinlet on particles’ size. 
The density of spray-dried powders was only affected by the fat content of the fresh milk, with the 
LFM samples presenting the highest values, in contrast to the HFM samples, due to the fact that fat is less 365 
dense then other components in the powders. It was not surprising that LFM samples were more 
hydrophilic (lower w) and presented higher wettability (better redispersibility in water), in line with what 
was observed before with solid dispersions of poorly water soluble drugs (19). During particle formation, it 
is possible that protein, either as free molecules or in micelles, deposited on the surface of the forming 
particle, lowering their surface energy. On the contrary, higher fat content milk, in which fat globules have 370 
the ability to disperse and migrate to the surface of the particles, produced a hydrophobic surface (40). 
Interestingly, some MFM samples have shown higher contact angles than HFM samples. One can 
hypothesize that, throughout drying, the re-arrangement of the milk components in these two types of milk 
was different leading to different fat / protein surface compositions.  The residual water might have been 
16 
 
the justification of the lowering w of HFM samples dried at 105°C which decreased the fraction of fat with 375 
impact on the redispersibility in water. Spreading coefficients indicate that milk components had a 
tendency to spread over theophylline making the properties of bulk particles independent of theophylline 
fraction, the latter more difficult to extract and quantify. 
Data from the FT-IR spectra was sensitive to the ratio between theophylline and milk components. 
As theophylline fraction increased, particularly above 0.31 in MFM and HFM powders, the signal due to 380 
milk components decreased until complete replacement by the theophylline signal, particularly in the 
region observed for the peaks of the proteins’ amides I and II in higher fat milks. This observation was 
harder to verify in spray-dried particles due to the fact that such particles presented a fat rich surface, 
particularly evident in MFM and HFM, with broad peaks overlapping those of the proteins (41–43). On the 
contrary, in powders with low theophylline fractions (e.g. 0.08 and 0.16) the presence of the N-H stretching 385 
in the region of 3120.96cm-1 was difficult to observe due to a dilution effect and overlap of the drug’s 
output. This means that the absence of peaks is due to the fractions of components in the powders, and 
not to the interaction between any component of the milk and theophylline. These observations are in 
agreement with that of a solid dispersion made of powdered skimmed milk as carrier of valsartan, a drug 
molecule which presents an amine group, as theophylline does (19). The potential interaction of lactose 390 
with theophylline (e.g. Maillard’s reaction) (44) was evaluated immediately after drying and 6 months later. 
Likely this potential interaction would have been reflected by the N-H bond of the drug and the O-H of the 
lactose. Data from FT-IR in the region of 1647-1630cm-1 revealed that no imine group was formed, thus, no 
reaction was deemed to have occurred. The DSC thermograms did not show any thermic events, 
particularly between 100-150°C or at higher temperatures (e.g. 220°C) (45) temperatures at which possible 395 
products of degradation might have been formed, as observed for other drugs and dosage forms (46,47). 
The presence of milk fat and protein components may have prevented the interaction between the drug 
and lactose (40). 
  The quantification of theophylline in dried powders indicated that Tinlet and milk fat content did not 
affect the quantity of theophylline in samples, in contrast to the fraction of theophylline. However, the 400 
17 
 
amount of theophylline in dried powders was not entirely reflected in powders above 0.31:1 ratio, 
particularly at 0.62:1 and 1:1 ratios (p < 0.05). However, since the analytical technique was previously 
validated, the partial recovery of theophylline may have been due to uncollected theophylline particles, i.e., 
partial loss of theophylline to the exhaust of the spray-drier, or an incomplete extraction of theophylline 
from the particles. This observation is supported by the low yields obtained when theophylline was dried 405 
alone from solutions. If a correlation between these observations is made, then one can say that milk 
decreases the loss of theophylline during the drying process by incorporation of theophylline molecules 
within milk components. 
The microbiological evaluation of the reconstituted powder (in-use stability) has shown that the 
Pharmacopeia criteria were met on the 1st day for samples stored at 25°C. After 2 days of reconstitution, 410 
criteria were met by all samples at 4°C and after 7 days only LFM samples met the criteria. These results are 
comparable to that (13.7 days) obtained  for pasteurized skimmed milk (LFM), stored at 5°C (48). 
Theophylline content in solution remained constant throughout the study in every extemporaneous 
sample. The lower microbial growth presented by samples dried at lower inlet air temperatures, suggests 
that the longer time taken to dry the droplets, resulted in a smaller microbial survival rate. 415 
In powders stored for 6 months, theophylline also remained chemically stable, but microbiological 
specifications were no longer observed, except for LFM. However, non-compliance was not dependent on 
MC, since LFM with a 6.4% MC passed the test. Samples with lower milk fractions were closer to 
acceptability than the others, which is not surprising if one considers that milk is an excellent microbial 
culture media.  420 
 
 
5. Conclusions 
The study has confirmed the potential of using fresh milk to produce powders as a solid dosage 
form to deliver drugs to children, as such or after extemporaneous reconstitution in water (or indeed, as a 425 
the starting point for other dosage forms). The work highlights an innovative approach of using milk as a 
18 
 
likely alternative platform to deliver drugs to the paediatric population of different age groups. The process 
and product presents several advantages, namely, the fact that drug is mixed with milk only, decreasing the 
toxicity concerns of the final formulation and incorporation of drug in solution promotes uniformity of 
content. An oral solid dosage form is suggested since theophylline content remained stable after 6 months 430 
of storage of powders, as well as after reconstitution in water. In-use and shelf-life stability of powders 
showed that LFM samples met the microbial criteria, at 4°C for 7 days and at 25°C for 6 months, 
respectively. Furthermore, no drug-milk interactions were observed. The use of different fresh milks, 
preferably LFM, should be considered as a possible drug-powder-solution formulation that, due to its 
likeliness to a well known food to children, would result in increased patient’s compliance. For parents, 435 
nurses and caregivers this composed pharmaceutical powder would be easy to prepare, requiring only 
reconstitution in water (simple due to the low contact angles exhibited), thus minimizing the problems 
related to dose flexibility and accuracy.  
To fully establish this approach, a further characterization of the system (namely in terms of drug 
entrapment and interaction between low solubility / hydrophobic drugs and milk fat components) and in 440 
vivo studies (e.g. to investigate the influence of fat on the digestion and release of the drug) are warranted. 
Furthermore, since the source of milk is likely to affect the final product, special attention should be paid to 
the specifications of the fresh milk used, to guarantee reproducibility. 
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Table 1 - Properties of the spray-dried milk powders and process characterization 1 
 
Tinlet 
/ 
Toutlet 
(°C) 
Fat 
Content 
(g) 
Property 
Theophylline : milk solids ratio (w/w) 
0:1 0.08:1 0.16:1 0.31:1 0.62:1 1:1 
1
0
5
 /
 6
8
 
O.3 
 
(LFM) 
Yield 42.0 33.7 45.8 52.7 49.9 53.6 
MC 4.9 6.4 4.7 5.7 5.5 6.4 
Assay 0.0 100.0 97.8 89.7 75.0 61.8 
d 3.3 3.1 3.5 3.5 3.6 3.7 
Span 1.25 0.90 1.17 1.20 1.44 1.26 
ρ 1.501 1.509 1.520 1.499 1.504 1.515 
ΘW 85.14 83.74 83.53 83.94 80.62 81.23 
ΘD 38.87 41.72 37.90 45.15 47.46 44.18 
   11.14 9.20 9.07 9.69 9.54 10.40 
   52.44 49.35 49.18 48.44 46.40 50.15 
4 
 
(MFM) 
Yield 39.2 56.6 54.2 36.6 38.5 54.1 
MC 6.1 6.5 8.5 4.5 5.3 4.1 
Assay 0.0 96.5 93.6 88.8 72.8 65.5 
d 3.3 3.3 3.0 3.6 3.7 3.5 
Span 1.30 1.30 1.08 1.12 1.42 1.29 
ρ 1.426 1.401 1.413 1.446 1.449 1.455 
ΘW 86.70 85.21 85.33 93.32 84.63 83.55 
ΘD 45.47 43.10 43.50 32.05 43.52 37.74 
   3.82 6.90 7.40 4.56 7.55 8.66 
   41.38 45.47 45.28 45.69 47.92 48.09 
9 
 
(HFM) 
Yield 28.4 38.9 36.6 46.6 33.8 37.4 
MC 7.1 4.8 10.3 5.9 9.4 4.2 
Assay 0.0 96.5 93.6 88.8 72.8 65.5 
d 3.4 3.4 3.7 3.6 3.4 3.8 
Span 1.28 1.14 1.25 1.23 1.28 1.24 
ρ 1.382 1.382 1.385 1.357 1.412 1.437 
ΘW 84.79 86.64 83.18 81.53 82.70 81.31 
ΘD 56.11 48.00 47.63 51.88 47.46 44.18 
   9.18 7.27 8.73 10.18 8.00 9.56 
   42.72 41.33 45.33 46.53 49.58 49.76 
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Table 1 - Properties of the spray-dried milk powders and process characterization 1 (cont.) 
 
Tinlet 
/ 
Toutlet 
(°C) 
Fat 
Content 
(g) 
Property 
Theophylline : milk solids ratio (w/w) 
0:1 0.08:1 0.16:1 0.31:1 0.62:1 1:1 
1
3
0
 /
 8
7
 
O.3 
 
(LFM) 
Yield 76.0 73.3 68.5 65.3 43.0 70.0 
MC 1.6 1.1 1.0 1.0 2.5 1.1 
Assay 0.0 101.4 103.8 97.7 78.3 61.2 
d 3.3 3.6 3.8 4.2 4.0 4.0 
Span 1.18 1.03 1.23 1.36 1.45 1.42 
ρ 1.493 1.491 1.498 1.501 1.504 1.498 
ΘW 85.50 84.73 85.36 86.29 87.17 85.23 
ΘD 40.32 31.77 30.65 39.11 47.95 44.78 
   8.23 8.78 9.04 5.08 9.73 11.33 
   48.49 45.02 46.38 43.25 48.02 49.47 
4 
 
(MFM) 
Yield 59.6 31.0 57.0 58.3 71.0 56.3 
MC 5.1 6.3 4.8 4.1 3.6 3.0 
Assay 0.0 102.9 102.5 89.5 74.9 66.0 
d 3.7 3.5 3.7 3.6 3.5 3.4 
Span 1.15 1.18 0.93 1.26 1.06 1.15 
ρ 1.386 1.431 1.409 1.397 1.417 1.433 
ΘW 92.55 83.95 85.54 83.38 85.31 79.76 
ΘD 45.42 42.54 42.67 44.55 41.36 41.96 
   5.16 8.37 9.45 4.98 8.07 8.77 
   43.66 46.55 47.43 44.94 46.50 47.84 
9 
 
(HFM) 
Yield 47.2 72.1 72.6 45.7 64.6 68.9 
MC 6.1 2.6 1.0 2.8 8.2 4.1 
Assay 0.0 94.03 98.9 102.2 79.1 64.9 
d 3.5 3.6 3.7 3.6 3.8 3.7 
Span 2.20 1.55 1.17 1.25 1.09 1.16 
ρ 1.389 1.244 1.287 1.336 1.361 1.386 
ΘW 85.72 86.62 93.51 92.76 85.71 81.69 
ΘD 49.17 47.58 40.97 43.90 42.67 38.83 
   5.42 5.37 4.64 5.61 9.10 8.70 
   40.82 40.69 43.73 43.66 46.84 47.76 
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Table 1 - Properties of the spray-dried milk powders and process characterization 1 (cont.) 555 
 
Tinlet 
/ 
Toutle
t 
(°C) 
Fat 
Content 
(g) 
Property 
Theophylline : milk solids ratio (w/w) 
0:1 0.08:1 0.16:1 0.31:1 0.62:1 1:1 
1
5
0
 /
 1
0
0
 
O.3 
 
(LFM) 
Yield 13.6 25.2 32.5 36.0 44.9 61.9 
MC 0.7 5.9 2.1 2.7 1.7 0.6 
Assay 0.0 101.8 97.3 81.6 75.8 58.6 
d 3.9 3.6 3.4 3.6 3.8 3.1 
Span 1.31 1.33 1.23 1.40 1.26 1.27 
ρ 1.426 1.552 1.515 1.501 1.486 1.476 
ΘW 84.01 82.96 85.69 85.11 86.28 86.33 
ΘD 47.54 49.35 47.98 47.07 33.29 43.95 
   12.30 12.25 5.63 9.02 8.00 7.16 
   48.63 47.34 42.35 46.57 45.04 44.80 
4 
 
(MFM) 
Yield 28.4 44.1 38.3 68.3 47.4 50.0 
MC 2.8 1.9 0.3 1.9 1.8 0.4 
Assay 0.0 102.8 93.8 89.5 75.8 61.3 
d 3.6 3.6 3.8 3.6 4.0 4.3 
Span 1.29 1.24 1.46 1.39 1.31 1.35 
ρ 1.407 1.376 1.386 1.396 1.418 1.424 
ΘW 91.99 87.05 83.72 86.01 93.45 82.28 
ΘD 41.88 43.35 37.69 38.30 32.85 37.10 
   5.17 4.70 8.67 4.67 4.49 8.72 
   45.13 45.72 48.63 46.37 46.66 50.43 
9 
 
(HFM) 
Yield 31.2 34.0 50.4 52.5 53.3 51.6 
MC 0.0 1.2 0.0 1.2 2.8 0.4 
Assay 0.0 100.7 87.1 88.7 76.6 47.6 
d 3.7 3.9 3.5 3.7 3.5 4.0 
Span 1.30 1.43 1.43 1.34 1.27 1.31 
ρ 1.296 1.298 1.309 1.326 1.367 1.384 
ΘW 84.07 92.72 92.66 87.61 93.36 86.85 
ΘD 53.63 48.81 51.10 49.14 43.71 47.92 
   5.51 5.44 5.68 8.91 4.98 5.11 
   39.13 40.68 40.01 46.20 42.35 41.82 
 
API ΘW ΘD       
Theophylline 
Raw Material 
77.33 48.46 11.64 49.24 
 
1 Coefficients of variation (CV) for the means and for all experiments were smaller than 2%. 
 
Yield - %; MC – Moisture Content (%); Assay – Theophylline content assayed by HPLC (%); d – Particle size 560 
(µm); ρ – Particle density (g/cm3); ΘW (⁰) - Contact angle in water; ΘD – Contact angle in diiodomethane;  
ϒp (mJ/m2) – Polar part; ϒs (mJ/m
2) – Surface Free Energy. 
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Table 2 - Evaluation of the effect of the Tinlet, fat content of milk and theophylline fraction in the properties of the spray-dried milk powders by one-way 
ANOVA. 
Factor 
Yield  
(%) 
Moisture Content 
(%) 
Particle Size  
(µm) 
Density  
(gcm-3) 
Polar Part  
(γp /mJ/m2) 
Surface Free Energy 
(γ /mJ/m2) 
Theophylline Assay 
(%) 
Effect MSqa p 1 Effect MSq p 1 Effect MSq p 1 Effect MSq p 1 Effect MSq p 1 Effect MSq p 1 Effect MSq p 1 
Tinlet 14.44 139.3 0.000 29.37 3.226 0.000 5.340 0.056 0.548 1.182 0.005 0.315 4.826 5.891 0.012 5.607 8.873 0.006 0.064 84.40 0.938 
Fat content of milk 0.043 217.8 0.957 0.700 6.758 0.501 0.135 0.067 0.874 84.71 0.001 0.000 4.924 5.872 0.011 2.564 9.835 0.087 0.004 5.521 0.996 
Theophylline Fraction 1.227 205.5 0.311 0.516 7.001 0.763 1.218 0.064 0.315 0.342 0.005 0.885 0.507 7.069 0.769 1.367 10.07 0.253 577.9 22.78 0.000 
 
a
 MSq – Mean Square 
1
 statistically significant result at p < 0.05 
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Table 3 – Works of adhesion and cohesion and spreading coefficients of samples containing milk and 
theophylline. 
 
Samples 
 
Tinlet (°C) 
 
Wc 
(mJ/m2) 
 
Wa 
(mJ/m2) 
12 21 
LF
M
 105 104.88 101.50 -3.38 3.02 
130 96.98 97.05 0.07 -1.43 
150 97.26 97.83 0.57 -0.65 
M
FM
 105 82.76 86.67 3.91 -11.81 
130 87.32 90.39 3.07 -8.09 
150 90.26 91.81 1.55 -6.67 
H
FM
 105 85.44 93.69 8.25 -4.79 
130 81.64 87.72 6.08 -10.76 
150 78.26 85.96 7.70 -12.52 
     
Theophylline 98.48 - - - 
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Annex 1: Preparation of theophylline : milk systems.  
Theophylline : Milk  
solid components ratio 
(w/w) 
Mass of theophylline in 2.5g 
of powdered milk 
(g) 
Volume of 
theophylline 
solution 
1
 
(mL) 
Volume of milk containing 2.5g 
of solid content 
(mL) 
LFM MFM HFM 
0:1 0.00 0.00 
27.30 23.78 20.12 
0.08:1 0.20 26.67 
0.16:1 0.45 59.73 
0.31:1 0.78 103.33 
0.62:1 1.55 206.67 
1:1 2.50 333.33 
 
1 volume withdrawn from a solution of theophylline (7.5 g/l) 
LFM – Low fat milk; MFM – Medium fat milk; HFM – High fat milk 
 
 
 
 
Annex 2: Yield and moisture content of spray-dried theophylline solutions1 
 
1  
Operating conditions: Tinlet = 130°C; airflow rate = 600 l/h; aspirator rate = 100%; and feed liquid rate = 4 mL/min). 
 
Theophylline in aqueous solution 
(w/v) 
Yield 
(%) 
Moisture content 
(%) 
0.08:1 20.59 2.0 
0.16:1 21.59 0.5 
0.31:1 19.18 0.9 
0.62:1 19.79 1.8 
1:1 30.04 0.4 
